BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 20, 2017
View Archived Issues
Florida Department of Health awards grant for gp96-based Zika vaccine development
Read More
DSMB recommends continuation of phase III trial of apabetalone
Read More
New phase III outcomes program for empagliflozin in chronic heart failure
Read More
Kisqali available for U.S. order through Biologics
Read More
Efficacy seen with CLS-003 digoxin/furosemide patch in treating cutaneous warts
Read More
Biosceptre obtains conditional ethics committee approval for phase I trial of BIL-03s
Read More
Phase II results for macitentan presented for pulmonary hypertension
Read More
Ergomed initiates European phase IIb study of PeproStat
Read More
Achillion Pharmaceuticals describes novel complement factor D inhibitors
Read More
Gachon University, Bio-Medical Science and Yoo Young Pharm patent mTOR inhibitors
Read More
Umecrine Cognition initiates phase Ib/IIa study of GR-3027 for hepatic encephalopathy
Read More
Yang Ji Chemical Co. and Han Wha Pharma Co. describe new JAK inhibitors
Read More
Sunshine Lake Pharma patents cathepsin K inhibitors
Read More
Abbvie discloses new sphingosine 1-phosphate receptor 5 modulators
Read More
Janssen-Cilag conducts oral bioavailability trial of JNJ-63623872/oseltamivir phosphate
Read More
Saniona updates plans for phase IIa study of Tesomet in Prader-Willi syndrome
Read More
AB Science's phase II/III trial of masitinib in ALS meets primary endpoint
Read More
Ipsen returns LRRK2-based research program in Parkinson's to Oncodesign
Read More
Japanese collaborators announce open innovation research on new cancer immunotherapy
Read More
Study suggests PARP-1 is a therapeutic target for treating Merkel cell carcinoma
Read More
CBT Pharmaceuticals begins phase I study of CBT-501 in advanced, relapsed or recurrent solid tumors
Read More
MDR3 and MRP1 found as poor prognostic markers in Wilm's tumor after SIOP-93-01 treatment protocol
Read More
